financetom
Business
financetom
/
Business
/
Mazda makes cost-saving effort as inflation threatens to drive up investment spending
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mazda makes cost-saving effort as inflation threatens to drive up investment spending
Mar 17, 2025 11:05 PM

TOKYO (Reuters) - Japanese automaker Mazda Motor ( MZDAF ) said on Tuesday it will keep investments in its electrification efforts in check by making use of partnerships and its existing manufacturing plants after inflation threatened to push up costs.

The automaker said it expects to keep its investment at around 1.5 trillion yen ($10.02 billion) for the period up to 2030 through its efforts, just as much as it had said in November 2022 it would be investing.

Without its cost-savings efforts, spending on investment for the period was likely to surge by a third compared to what the company expected initially to around 2 trillion yen due to inflation, Mazda ( MZDAF ) said.

As part of its "lean asset" strategy it unveiled on Tuesday, Mazda ( MZDAF ) planned to produce an electric vehicle that it will launch in 2027 on an existing production line on which it already makes cars powered by internal combustion engines.

By using an existing line instead of building a dedicated EV plant, the company would keep down the required investment amount by about 85% and cut the production lead time by around 80% for the vehicle.

Mazda ( MZDAF ) already has a number of partnerships in various areas, such as with much bigger peer Toyota Motor ( TM ) on the development of electronic architecture, and Denso ( DNZOF ), one of the world's biggest automotive suppliers.

Mazda ( MZDAF ) will need to further step up its collaboration with companies in the automotive industry if it wants to retain its international competitiveness as a Japanese automaker, CEO Masahiro Moro told reporters.

Toyota ( TM ) owns a 5.1% stake in the automaker.

($1 = 149.6500 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Peyto Exploration Develops Record 76.2 Million MMboe Reserves in 2024
Peyto Exploration Develops Record 76.2 Million MMboe Reserves in 2024
Feb 21, 2025
07:25 AM EST, 02/21/2025 (MT Newswires) -- Peyto Exploration & Development ( PEYUF ) overnight Thursday said its 2024 drilling program developed a record 76.2 million barrels of oil equivalent (MMboe) of new Proved Developed Producing (PDP) reserves. The company estimates a total base decline rate of 27% this year, from December's monthly average production of 136 Mboe/d. Its capital...
Pony AI's Robotaxis Hit Guangzhou's High-Demand Routes: Details
Pony AI's Robotaxis Hit Guangzhou's High-Demand Routes: Details
Feb 21, 2025
Pony AI Inc. ( PONY ) shares are trading higher premarket on Friday after the company launched paid robotaxi services connecting Guangzhou’s city center with Baiyun International Airport and South Railway Station. The company said it is the first and only approved to operate on these high-demand routes. Pony.ai’s robotaxi service offers residents and tourists a seamless, autonomous travel option. Riders can book via the PonyPilot App, with fares...
Stellantis Reportedly Halts Assembly Plant in Canada Amid Product Strategy Review
Stellantis Reportedly Halts Assembly Plant in Canada Amid Product Strategy Review
Feb 21, 2025
07:26 AM EST, 02/21/2025 (MT Newswires) -- Stellantis ( STLA ) halted work on its Jeep Compass sport utility vehicle model and activities at its assembly plant in Ontario, Canada as the company evaluates its product strategy in North America, news outlets reported Thursday, citing a statement from a company spokesperson. Citing a June 2024 company fact sheet, Reuters said...
Johnson & Johnson's Subcutaneous Ulcerative Colitis Treatment Shows 'Significant' Improvements
Johnson & Johnson's Subcutaneous Ulcerative Colitis Treatment Shows 'Significant' Improvements
Feb 21, 2025
07:26 AM EST, 02/21/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that data from a phase 3 study of Tremfya subcutaneous induction therapy in adults with moderately to severely active ulcerative colitis showed statistically significant and clinically meaningful improvements compared to a placebo. The company said the results for the drug, also called guselkumab, were consistent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved